Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells

被引：113

作者：

Cieri, Nicoletta ^{[1
,2
]}

Greco, Raffaella ^{[1
]}

Crucitti, Lara ^{[1
,3
]}

Morelli, Mara ^{[1
]}

Giglio, Fabio ^{[1
]}

Levati, Giorgia ^{[1
]}

Assanelli, Andrea ^{[1
]}

Carrabba, Matteo G. ^{[1
]}

Bellio, Laura ^{[4
]}

Milani, Raffaella ^{[4
]}

Lorentino, Francesca ^{[1
]}

Stanghellini, Maria Teresa Lupo ^{[1
]}

De Freitas, Tiago ^{[1
]}

Marktel, Sarah ^{[1
]}

Bernardi, Massimo ^{[1
]}

Corti, Consuelo ^{[1
]}

Vago, Luca ^{[1
,3
]}

Bonini, Chiara

Ciceri, Fabio ^{[1
,3
]}

Peccatori, Jacopo ^{[1
]}

机构：

[1] Ist Sci San Raffaele, Hematol & Bone Transplantat Unit, Div Regenerat Med Stem Cells & Gene Therapy, I-20132 Milan, Italy

[2] Ist Sci San Raffaele, Expt Hematol Unit, Div Immunol Transplantat & Infect Dis, I-20132 Milan, Italy

[3] Ist Sci San Raffaele, Mol & Funct Immunogenet Unit, Div Regenerat Med Stem Cells & Gene Therapy, I-20132 Milan, Italy

[4] Ist Sci San Raffaele, Immunohematol & Transfus Med Unit, Div Regenerat Med Stem Cells & Gene Therapy, I-20132 Milan, Italy

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2015年 / 21卷 / 08期

关键词：

Post-transplantation cyclophosphamide; Sirolimus; Peripheral blood stem cell transplantation; Allogeneic stem cell transplantation; Haploidentical transplantation; VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; HUMAN-LEUKOCYTE ANTIGEN; REGULATORY T-CELLS; HIGH-RISK; ACUTE-LEUKEMIA; HEMATOLOGIC MALIGNANCIES; MISMATCHED HLA; PHASE-II; RAPAMYCIN;

D O I：

10.1016/j.bbmt.2015.04.025

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Haploidentical hematopoietic stem cell transplantation (HSCT) performed using bone marrow (BM) grafts and post-transplantation cyclophosphamide (PTCy) has gained much interest for the excellent toxicity profile after both reduced-intensity and myeloablative conditioning. We investigated, in a cohort of 40 high-risk hematological patients, the feasibility of peripheral blood stem cells grafts after a treosulfan-melphalan myeloablative conditioning, followed by a PTCy and sirolimus-based graft-versus-host disease (GVHD) prophylaxis (Sir-PTCy). Donor engraftment occurred in all patients, with full donor chimerism achieved by day 30. Post-HSCT recovery of lymphocyte subsets was broad and fast, with a median time to CD4 > 200/mu L of 41 days. Cumulative incidences of grade II to IV and III-IV acute GVHD were 15% and 7.5%, respectively, and were associated with a significant early increase in circulating regulatory T cells at day 15 after HSCT, with values < 5% being predictive of subsequent GVHD occurrence. The 1-year cumulative incidence of chronic GVHD was 20%. Nonrelapse mortality (NRM) at 100 days and 1 year were 12% and 17%, respectively. With a median follow-up for living patients of 15 months, the estimated 1-year overall and disease-free survival (DFS) was 56% and 48%, respectively. Outcomes were more favorable in patients who underwent transplantation in complete remission (1-year DFS 71%) versus patients who underwent transplantation with active disease (DFS, 34%; P = .01). Overall, myeloablative haploidentical HSCT with peripheral blood stem cells (PBSC) and Sir-PTCy is a feasible treatment option: the low rates of GVHD and NRM as well as the favorable immune reconstitution profile pave the way for a prospective comparative trial comparing BM and PBSC in this specific transplantation setting. (C) 2015 American Society for Blood and Marrow Transplantation.

引用

页码：1506 / 1514

页数：9

共 63 条

[1] Allo-HLA reactivity of virus-specific memory T cells is common
Amir, Avital L.
D'Orsogna, Lloyd J. A.
Roelen, Dave L.
van Loenen, Marleen M.
Hagedoorn, Renate S.
de Boer, Renate
van der Hoorn, Menno A. W. G.
Kester, Michel G. D.
Doxiadis, Ilias I. N.
Falkenburg, J. H. Frederik
Claas, Frans H. J.
Heemskerk, Mirjam H. M.
[J]. BLOOD, 2010, 115 (15) : 3146 - 3157
[2] Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation
Armand, Philippe
Kim, Haesook T.
Logan, Brent R.
Wang, Zhiwei
Alyea, Edwin P.
Kalaycio, Matt E.
Maziarz, Richard T.
Antin, Joseph H.
Soiffer, Robert J.
Weisdorf, Daniel J.
Rizzo, J. Douglas
Horowitz, Mary M.
Saber, Wael
[J]. BLOOD, 2014, 123 (23) : 3664 - 3671
[3] Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning
Armand, Philippe
Gannamaneni, Supriya
Kim, Haesook T.
Cutler, Corey S.
Ho, Vincent T.
Koreth, John
Alyea, Edwin P.
LaCasce, Ann S.
Jacobsen, Eric D.
Fisher, David C.
Brown, Jennifer R.
Canellos, George P.
Freedman, Arnold S.
Soiffer, Robert J.
Antin, Joseph H.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) : 5767 - 5774
[4] Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype
Aversa, F
Tabilio, A
Velardi, A
Cunningham, I
Terenzi, A
Falzetti, F
Ruggeri, L
Barbabietola, G
Aristei, C
Latini, P
Reisner, Y
Martelli, MF
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (17) : 1186 - 1193
[5] Full haplotype-mismatched hematopoietic stem-cell transplantation: A phase II study in patients with acute leukemia at high risk of relapse
Aversa, F
Terenzi, A
Tabilio, A
Falzetti, F
Carotti, A
Ballanti, S
Felicini, R
Falcinelli, F
Velardi, A
Ruggeri, L
Aloisi, T
Saab, JP
Santucci, A
Perruccio, K
Martelli, MP
Mecucci, C
Reisner, Y
Martelli, MF
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) : 3447 - 3454
[6] T-Cell-Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation
Bashey, Asad
Zhang, Xu
Sizemore, Connie A.
Manion, Karen
Brown, Stacey
Holland, H. Kent
Morris, Lawrence E.
Solomon, Scott R.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (10) : 1310 - 1316
[7] Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells
Battaglia, M
Stabilini, A
Roncarolo, MG
[J]. BLOOD, 2005, 105 (12) : 4743 - 4748
[8] MARROW TRANSPLANTATION FROM RELATED DONORS OTHER THAN HLA-IDENTICAL SIBLINGS
BEATTY, PG
CLIFT, RA
MICKELSON, EM
NISPEROS, BB
FLOURNOY, N
MARTIN, PJ
SANDERS, JE
STEWART, P
BUCKNER, CD
STORB, R
THOMAS, ED
HANSEN, JA
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (13) : 765 - 771
[9] Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes
Bhamidipati, P. K.
DiPersio, J. F.
Stokerl-Goldstein, K.
Rashidi, A.
Gao, F.
Uy, G. L.
Westervelt, P.
Vij, R.
Schroeder, M. A.
Abboud, C. N.
Keller, J. W.
Fehniger, T. A.
Romee, R.
[J]. BONE MARROW TRANSPLANTATION, 2014, 49 (08) : 1124 - 1126
[10] Bone Marrow Compared with Peripheral Blood Stem Cells for Haploidentical Transplantation with a Nonmyeloablative Conditioning Regimen and Post-transplantation Cyclophosphamide
Castagna, Luca
Crocchiolo, Roberto
Furst, Sabine
Bramanti, Stefania
El Cheikh, Jean
Sarina, Barbara
Granata, Angela
Mauro, Elisa
Faucher, Catherine
Mohty, Bilal
Harbi, Samia
Chabannon, Christian
Carlo-Stella, Carmelo
Santoro, Armando
Blaise, Didier
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (05) : 724 - 729

← 1 2 3 4 5 6 7 →